Association of BRAFV600E mutation with clinical pathological features in papillary thyroid carcinoma:meta-analysis
10.3760/cma.j.issn.1673-0860.2014.09.012
- VernacularTitle:BRAFV600E基因突变和甲状腺乳头状癌临床病理特征关联性的Meta分析
- Author:
Kangkang YAN
1
;
Xuejun LIN
;
Shuang LI
;
Honghong BAO
;
Longyu ZHAO
;
Xin LIU
Author Information
1. 吉林大学公共卫生学院流行病与卫生统计学教研室
- Keywords:
Thyroid neoplasms;
Carcinoma,papillary;
Proto-oncogene protein B-raf;
Mutation;
Patholog clinical;
Meta-analysis
- From:
Chinese Journal of Otorhinolaryngology Head and Neck Surgery
2014;49(9):759-764
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the association between BRAF600E mutation and pathological features in papillary thyroid carcinoma (PTC).Methods The raleted studies were searched through Medline,PubMed,and Web of Science,and meta-analysis was used to calculate the OR and 95％ CI of the study results.Results A total of 52 studies including 12 029 PTC patients was identified.The prevalence of BRAFV600EE mutation in PTC was 57.85％.There was a closed association between the BRAFV600E mutation and pathological features,including advanced TNM stage (OR =1.89,95％ CI 1.58-2.27),lymph node metastasis (OR =1.74,95％ CI 1.42-2.14),multifocality (OR =1.25,95％ CI 1.07-1.46),and recurrence (OR =2.26,95％ CI 1.25-4.09) of PTC.For Asians with PTC,the association between the BRAFV600E mutation and pathological features was indicated for advanced TNM stage(OR =1.56,95％ CI 1.24-1.96) and lymph node metastasis(OR =1.57,95％ CI 1.25-1.99).For Europeans with PTC,the association between the BRAFV600E mutation and pathological features was indicated for advanced TNM stage (OR =2.63,95％ CI 2.10-3.30),lymph node metastasis(OR =1.97,95％ CI 1.19-3.25),and multifocality (OR =1.35,95％ CI 1.01-1.80).Conclusion There were associations between the BRAFV600EE mutation and advanced TNM stage,lymph node metastasis,multifocality,and recurrence of PTC.
